ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

ANALYSIS OF IMPLICATION OF AGE ON CARDIO TOXICITY IN PATIENTS TREATED WITH 5FU/LV IN BREAST CANCER PATIENTS

AUTHORS:

Dr Ali Naveed, Dr Usama Yaqub, Dr Ahmad Nadeem

ABSTRACT:

Introduction: Fluoropyrimidine chemotherapy [5-fluorouracil [5-FU] and the prodrug capecitabine] are the cornerstone drugs in the treatment of gastrointestinal [GI], breast, and other solid malignancies. Aims and objectives: The basic aim of the study is to analyse the implication of demographic values on cardio toxicity in patients treated with 5FU/LV in breast cancer patients. Material and methods: This clinical study was conducted in King Edward Medical University, Lahore during January 2018 to July 2019. This study was done with the permission of ethical committee of hospital. The data was collected from 50 patients of breast cancer. These evaluable patients [median age 55] were treated with high dose leucovorin regimen of 5-FU and fifteen patients included in the study, were subjected to low dose leucovorin regimen of 5-FU chemotherapy. Results: The data was collected from 50 patients of breast cancer. Less well described is the chest pain associated with continuous infusion 5-FU. Chest pain associated with continuous infusion may also occur with the first or second chemotherapy cycle, typically between 24–72 hours after infusion initiation. The pain may be atypical compared to classical angina, i.e., occurring at rest, resolving spontaneously. Symptoms may also recur cyclically during the infusion and persist following infusion completion. Many patients find these symptoms tolerable and complete the planned infusion course. Conclusion: It is concluded that cardio toxic potential is verified in both the treatment schedules of infusional and bolus 5-FU with high and low dose leucovorin implying varying attributes. Key words: Cancer, Infusion, Symptoms, Leucovorin

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.